Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study
Lenvatinib-based triple therapy tends to prolong OS compared to bevacizumab, although the PFS was similar between the two groups. Patients aged ≤65 years, without a history of hepatitis B virus infection, with BCLC-C stage, ALT ≤40 U/L, platelets ≥100 × 10<sup>9</sup>/L, or log 10 AFP ≥1.40 are likely to benefit more from lenvatinib-based triple therapy.
Authors
- Shunli Shen (ORCID: https://orcid.org/0000-0001-7931-9193)
- Zhaolong Pan (ORCID: https://orcid.org/0000-0002-1474-5113)
- Yangxun Pan (ORCID: https://orcid.org/0000-0002-3887-5852)
- Yang Zhao (ORCID: https://orcid.org/0000-0003-3226-8127)
- Hui‐Chuan Sun (ORCID: https://orcid.org/0000-0003-3761-7058)
- Tao Peng (ORCID: https://orcid.org/0000-0001-6133-7078)
- Renan Jin
- Ming Kuang (ORCID: https://orcid.org/0000-0002-7397-5779)
- Jian‐Hong Zhong (ORCID: https://orcid.org/0000-0002-1494-6396)
- Yongyi Zeng (ORCID: https://orcid.org/0000-0001-8823-698X)
- Xiao Liang (ORCID: https://orcid.org/0000-0002-2476-7332)
- Xiaoyi Shi
- Ledu Zhou (ORCID: https://orcid.org/0000-0003-0702-0429)
- Haitao Zhao (ORCID: https://orcid.org/0000-0002-8765-3690)
- Kuan Hu (ORCID: https://orcid.org/0000-0002-8698-1369)
- Kui Wang (ORCID: https://orcid.org/0000-0002-4756-9267)
- Jianwei Liu (ORCID: https://orcid.org/0000-0003-2965-3518)
- Dongxu Wang (ORCID: https://orcid.org/0000-0002-1333-8946)
- Wei Zhang (ORCID: https://orcid.org/0000-0003-2255-5405)
- Xiaoyun Zhang (ORCID: https://orcid.org/0000-0003-1257-379X)
- Tao Li (ORCID: https://orcid.org/0000-0002-5108-1774)
- Linlin Fu
- Hongzhi Liu (ORCID: https://orcid.org/0000-0001-7102-6855)
- Junbo Cao
- Xiaobo Yang (ORCID: https://orcid.org/0000-0002-1098-3165)
- Xiao‐Dong Zhu (ORCID: https://orcid.org/0000-0001-9864-6763)
- Tianfu Wen (ORCID: https://orcid.org/0000-0002-8260-7601)
- Shuijun Zhang (ORCID: https://orcid.org/0000-0002-0599-3289)
- Huikai Li (ORCID: https://orcid.org/0000-0003-4864-4991)
- Dongming Liu
- Chuangye Han
- Shanzhi Gu
- Xihao Zhang
- Bangde Xiang
- Tianqiang Song (ORCID: https://orcid.org/0000-0001-6465-4300)
- Li Xu
Institutions
- Fujian Medical University (CN)
- Central South University (CN)
- Sun Yat-sen University (CN)
- Guangxi Medical University (CN)
- Second Military Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sichuan University (CN)
- Fudan University (CN)
- Peking Union Medical College Hospital (CN)
- Sir Run Run Shaw Hospital (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- West China Hospital of Sichuan University (CN)
- Hunan Cancer Hospital (CN)
- Mengchao Hepatobiliary Hospital (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Xiangya Hospital Central South University (CN)
- Qilu Hospital of Shandong University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Liver Cancer
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1159/000545545
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.97
Funders
- Fudan University
- Tianjin Medical University